References
- Shiratori O, Kasai H, Uchida N, et al. Anti-tumor activi-ty of 254-S, a platinum complex, in rodents. In: Ishigami J (Ed.), Recent Advances in Chemotherapy, University of Tokyo Press, Tokyo, 1985: 635-636.
- Kameyama Y, Okazaki N, Nakagawa M, et al. Nephrotoxicity of a new platinum compound, 254-S, evaluat-ed with rat kidney cortical slices. Toxicol Lett 1990; 52 (1): 15–24.
- Koenuma M, Kasai H, Uchida N, et al. Pharmacokinetic correlation between experimental and clinical effects on human non-small cell cancers of cis-diammineglycolatoplat-inum (254-S) and cisdiamminedichloroplatinum. Anticancer Res 1995; 15 (2): 417–421.
- Fukuda M, Shinkai T, Eguchi F, et al. Phase II study of (glycolate-0,0') diammine platinum (II), a novel platinum com-plex, in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 1990; 26 (6): 393–396.
- Furuse K, Fukuoka M, Kurita Y, et al. A phase II clinical study of cis diammine glycolato platinum, 254-S, for primary lung cancer. Jpn J Cancer Chemother 1992; 19 (6): 879-884. (Japanese)
- Hirose T, Horichi N, Ohmori T, et al. Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer. Lung Cancer 2003; 39 (1): 91–97.
- Kurata T, Tamura K, Yamamoto N, et al. Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer. Br J Cancer 2004; 90 (11): 2092–2096.
- Oshita F, Yamada K, Kato Y, et al. Phase I/II study of escalating of nedaplatin in combination with irinotecan for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2003; 52 (1): 73–78.
- Oshita F, Yamada K, Saito H, et al. Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer. J Exp Ther Oncol 2004; 4 (4): 343–348.
- Tsuda H, Hashiguchi Y, Nishimura S, et al. Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor sup-port in patients with advanced or recurrent cervical cancer. Br J Cancer 2004; 91 (6): 1032–1037.
- Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. For the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Eng J Med 2002; 346 (2): 92–98.
- Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non—small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19 (13): 3210–3218.
- Takigawa N, Segawa Y, Ueoka H, et al. Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small cell lung cancer. Cancer Chemother Pharmacol 2000; 46 (4): 272–278.
- Å@Alberts DS, Fanta PT, Running KL, et al. In vitro Phase II comparison of the cytotoxicity of a novel platinum analog, nedapatin (254-S), with that of cisplatin and carbo-platin against fresh human ovarian cancers. Cancer Chemother Pharmacol 1997; 39 (6): 493–497.
- Å@Yamada H, Uchida N, Maekawa R, et al. Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel. Cancer Lett 2001; 172 (1): 17–25.
- Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with pacli-taxel/cisplatin in patients with advanced non-small cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13 (10): 1539–1549.
- Sekine I, Nokihara H, Horiike A, et al. Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma. Br J Cancer 2004; 90 (6): 1125–1128.
- Koizuimi T, Kubo K, Shinozaki S, et al. Pharmacokinetic evaluation of (glycolao-0,0') diammine plat-inum (II) in lung lymph in sheep. Jpn J Cancer Res 1993; 84 (4): 468–473.